Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Detection of nirsevimab-resistant RSV-B variants in children carrying the F:N201T substitution through genomic surveillance, Spain, 2025/26 season. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
GISAID: from vision to reality.
10.2807/1560-7917.es.2017.22.13.30494 · 2017 · External reference
Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein.
10.1371/journal.ppat.1005035 · 2015 · External reference
Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants.
10.1093/cid/ciaa951 · 2021 · External reference
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.
10.1016/s0140-6736(22)00478-0 · 2022 · External reference
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape.
10.1016/s1473-3099(22)00291-2 · 2023 · External reference
Two-season effectiveness of a single nirsevimab dose against RSV hospitalisation in healthy term-born infants: a population-based case-control study, Spain, October 2023 to March 2025.
10.2807/1560-7917.es.2026.31.9.2500593 · 2026 · External reference
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.
10.1126/scitranslmed.aaj1928 · 2017 · External reference
Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study.
10.1016/s1473-3099(24)00570-x · 2025 · External reference
Mutational constraints on RSV F and its neutralization by antibodies.
External reference
Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data.
10.1016/s1473-3099(23)00062-2 · 2023 · External reference
Prevalence and significance of substitutions in the fusion protein of respiratory syncytial virus resulting in neutralization escape from antibody MEDI8897.
10.1093/infdis/jiy189 · 2018 · External reference
